Ken Griffin Trinity Biotech PLC Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.38 - $0.7 $12,354 - $22,759	32,513 New	32,513 $13,000
Q2 2023 Aug 14, 2023	BUY	$0.84 - $1.14 $12,894 - $17,500	15,351 Added 68.93%	37,622 $35,000
Q1 2023 May 15, 2023	BUY	$0.87 - $1.18 $19,375 - $26,279	22,271 New	22,271 $20,000
Q4 2021 Feb 14, 2022	BUY	$1.43 - $2.25 $1,773 - $2,790	1,240 Added 7.03%	18,884 $27,000
Q3 2021 Nov 15, 2021	SELL	$1.82 - $2.94 $4,076 - $6,585	-2,240 Reduced 11.27%	17,644 $38,000
Q2 2021 Aug 16, 2021	BUY	$2.77 - $4.18 $14,777 - $22,300	5,335 Added 36.67%	19,884 $58,000
Q1 2021 May 17, 2021	SELL	$3.26 - $6.64 $122,999 - $250,527	-37,730 Reduced 72.17%	14,549 $54,000
Q3 2020 Nov 16, 2020	BUY	$1.68 - $3.17 $70,850 - $133,688	42,173 Added 417.31%	52,279 $105,000
Q2 2020 Aug 14, 2020	BUY	$0.88 - $2.55 $8,893 - $25,770	10,106 New	10,106 $22,000

30.2K

Ticker TRIB
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 38,107,600
Market Cap $46.5M
Description
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious dis...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.